Healthcare provider profile · identity verified

John David Schaffhausen, MD

Family Practice · MAPLE GROVE, MN · NPI 1912936428

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	669	185
Amlodipine Besylate	Amlodipine Besylate	540	148
Lisinopril	Lisinopril	432	122
Losartan Potassium	Losartan Potassium	321	90
Metoprolol Succinate	Metoprolol Succinate	314	97
Levothyroxine Sodium	Levothyroxine Sodium	283	71
Simvastatin	Simvastatin	266	75
Metformin Hcl	Metformin Hcl	263	81
Rosuvastatin Calcium	Rosuvastatin Calcium	253	82
Omeprazole	Omeprazole	240	76
Sertraline Hcl	Sertraline Hcl	191	55
Tamsulosin Hcl	Tamsulosin Hcl	164	51
Hydrochlorothiazide	Hydrochlorothiazide	159	48
Furosemide	Furosemide	146	55
Pantoprazole Sodium	Pantoprazole Sodium	145	41
Gabapentin	Gabapentin	124	40
Trazodone Hcl	Trazodone Hcl	116	38
Metoprolol Tartrate	Metoprolol Tartrate	112	32
Albuterol Sulfate Hfa	Albuterol Sulfate	109	38
Atenolol	Atenolol	100	28
Eliquis	Apixaban	93	31
Warfarin Sodium	Warfarin Sodium	90	20
Alprazolam	Alprazolam	89	20
Oxycodone Hcl	Oxycodone Hcl	87	28
Glimepiride	Glimepiride	85	25
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	85	18
Clonazepam	Clonazepam	83	12
Tramadol Hcl	Tramadol Hcl	82	15
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	80	17
Allopurinol	Allopurinol	77	23
Famotidine	Famotidine	76	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	73	22
Clopidogrel	Clopidogrel Bisulfate	72	23
Tizanidine Hcl	Tizanidine Hcl	65	20
Escitalopram Oxalate	Escitalopram Oxalate	63	15
Zolpidem Tartrate	Zolpidem Tartrate	60	13
Pravastatin Sodium	Pravastatin Sodium	59	15
Fluoxetine Hcl	Fluoxetine Hcl	56	20
Methocarbamol	Methocarbamol	54	15
Trulicity	Dulaglutide	53	11
Fluticasone Propionate	Fluticasone Propionate	52	13
Prednisone	Prednisone	52	33
Ondansetron Hcl	Ondansetron Hcl	50	suppressed
Carvedilol	Carvedilol	49	16
Xarelto	Rivaroxaban	48	17
Jardiance	Empagliflozin	45	12
Alendronate Sodium	Alendronate Sodium	44	16
Ozempic	Semaglutide	41	suppressed
Potassium Chloride	Potassium Chloride	41	15
Citalopram Hbr	Citalopram Hydrobromide	40	13
Hydralazine Hcl	Hydralazine Hcl	39	suppressed
Metformin Hcl Er	Metformin Hcl	39	12
Duloxetine Hcl	Duloxetine Hcl	37	14
Lorazepam	Lorazepam	37	suppressed
Bupropion Xl	Bupropion Hcl	36	suppressed
Lovastatin	Lovastatin	36	11
Valacyclovir	Valacyclovir Hcl	36	15
Chlorthalidone	Chlorthalidone	35	11
Azithromycin	Azithromycin	32	24
Irbesartan	Irbesartan	31	suppressed
Glipizide	Glipizide	30	suppressed
Baclofen	Baclofen	29	suppressed
Glycopyrrolate	Glycopyrrolate	29	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	29	12
Pioglitazone Hcl	Pioglitazone Hcl	29	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Torsemide	Torsemide	28	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	28	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	12
Montelukast Sodium	Montelukast Sodium	26	suppressed
Ibuprofen	Ibuprofen	25	suppressed
Pregabalin	Pregabalin	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	12
Ondansetron Odt	Ondansetron	24	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Amoxicillin	Amoxicillin	19	14
Doxycycline Hyclate	Doxycycline Hyclate	19	17
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	17
Spironolactone	Spironolactone	19	suppressed
Gemfibrozil	Gemfibrozil	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Glipizide Er	Glipizide	16	suppressed
Morphine Sulfate Er	Morphine Sulfate	16	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Fluconazole	Fluconazole	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Klor-Con M20	Potassium Chloride	14	suppressed
Nitroglycerin	Nitroglycerin	14	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Cephalexin	Cephalexin	12	suppressed
Verapamil Hcl	Verapamil Hcl	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Dutasteride	Dutasteride	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Estradiol	Estradiol	11	suppressed
Finasteride	Finasteride	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Temazepam	Temazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error